Stoke Therapeutics reports 2023 net loss $104.7M; cash $201.4M to fund to end 2025

Stoke Therapeutics, Inc.

Cash, equivalents & marketable securities $201.4M as of Dec 31, 2023; expected to fund operations through end of 2025.
Net loss for FY 2023 was $104.7M ($2.38 per share) vs $101.1M ($2.60 per share) in 2022.
Revenue from Acadia collaboration fell to $8.8M from $12.4M YoY.
R&D expenses $82.2M (2022: $77.8M); G&A $41.3M (2022: $38.9M), driven by STK-001 and STK-002 development.
Q4 2023 net loss $27.0M ($0.60 per share) vs $25.7M ($0.65 per share) in Q4 2022.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Stoke Therapeutics, Inc. reported the full year ended December 31, 2023 results: revenue $8.8 million, net income $104.7 million, or $2.38 per share, EPS $2.38 per share.

Period: the full year ended December 31, 2023
Revenue: $8.8 million
Net income: $104.7 million, or $2.38 per share
EPS: $2.38 per share
Result: reported results

Exact text from the filing

Revenue recognized for upfront license fees and services provided from a License and Collaboration Agreement with Acadia Pharmaceuticals for the year ended December 31, 2023 was $8.8 million, compared to $12.4 million, for the year ended December 31, 2022.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-035908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.